Tag Archives: Blueprint Medicines

November, 2018

June, 2018

November, 2017

September, 2016

March, 2016

  • 16 March

    Blueprint Medicines and Roche Enter Cancer Immunotherapy Deal

    CAMBRIDGE, Mass., March 15, 2016 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today announced that it has entered into a worldwide collaboration and exclusive license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, …

March, 2015